AIM ImmunoTech (AIM) Equity Ratio (2018 - 2025)
Historic Equity Ratio for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to 1.11.
- ImmunoTech's Equity Ratio fell 61613.67% to 1.11 in Q3 2025 from the same period last year, while for Sep 2025 it was 1.11, marking a year-over-year decrease of 61613.67%. This contributed to the annual value of 0.15 for FY2024, which is 12908.44% down from last year.
- ImmunoTech's Equity Ratio amounted to 1.11 in Q3 2025, which was down 61613.67% from 1.59 recorded in Q2 2025.
- In the past 5 years, ImmunoTech's Equity Ratio ranged from a high of 0.9 in Q2 2023 and a low of 1.59 during Q2 2025
- Over the past 3 years, ImmunoTech's median Equity Ratio value was 0.26 (recorded in 2024), while the average stood at 0.03.
- Its Equity Ratio has fluctuated over the past 5 years, first plummeted by 5668.43% in 2024, then tumbled by 61613.67% in 2025.
- Quarter analysis of 3 years shows ImmunoTech's Equity Ratio stood at 0.53 in 2023, then plummeted by 129.08% to 0.15 in 2024, then crashed by 620.23% to 1.11 in 2025.
- Its Equity Ratio stands at 1.11 for Q3 2025, versus 1.59 for Q2 2025 and 0.62 for Q1 2025.